Liquid biopsy for therapy monitoring in early-stage non-small cell lung cancer
説明
<jats:title>Abstract</jats:title><jats:p>Liquid biopsy is now considered a valuable diagnostic tool for advanced metastatic non-small cell lung cancer (NSCLC). In NSCLC, circulating tumor DNA (ctDNA) analysis has been shown to increase the chances of identifying the presence of targetable mutations and has been adopted by many clinicians owing to its low risk. Serial monitoring of ctDNA may also help assess the treatment response or for monitoring relapse. As the presence of detectable plasma ctDNA post-surgery likely indicates residual tumor burden, studies have been performed to quantify plasma ctDNA to assess minimal residual disease (MRD) in early-stage resected NSCLC. Most data on utilizing liquid biopsy for monitoring MRD in early-stage NSCLC are from small-scale studies using ctDNA. Here, we review the recent research on liquid biopsy in NSCLC, not limited to ctDNA, and focus on novel methods such as micro RNAs (miRNA) and long non-coding (lncRNA).</jats:p>
収録刊行物
-
- Molecular Cancer
-
Molecular Cancer 20 (1), 82-, 2021-06-01
Springer Science and Business Media LLC
- Tweet
キーワード
- Tumor
- Lung Neoplasms
- Therapy monitoring
- Liquid biopsy
- Carcinoma
- Liquid Biopsy
- 610
- Neoplasms. Tumors. Oncology. Including cancer and carcinogens
- ctDNA
- minimal residual disease (MRD)
- lncRNA
- Carcinoma, Non-Small-Cell Lung
- Biomarkers, Tumor
- Circulating nucleic acid
- Humans
- Non-Small-Cell Lung
- ctRNA
- Cell-Free Nucleic Acids
- Early-stage non-small cell lung cancer (NSCLC)
- Biomarkers
- RC254-282
- miRNA